PT  - JOURNAL ARTICLE
AU  - Gharbharan, Arvind
AU  - Jordans, Carlijn C.E.
AU  - Geurtsvankessel, Corinne
AU  - den Hollander, Jan G.
AU  - Karim, Faiz
AU  - Mollema, Femke P. N.
AU  - Stalenhoef-Schukken, Janneke E.
AU  - Dofferhoff, Anthonius
AU  - Ludwig, Inge
AU  - Koster, Adrianus
AU  - Hassing, Robert-Jan
AU  - Bos, Jeannet C.
AU  - van Pottelberge, Geert R.
AU  - Vlasveld, Imro N.
AU  - Ammerlaan, Heidi S. M.
AU  - van Leeuwen-Segarceanu, Elena M.
AU  - Miedema, Jelle
AU  - van der Eerden, Menno
AU  - Papageorgiou, Grigorios
AU  - Boekhorst, Peter te
AU  - Swaneveld, Francis H.
AU  - Katsikis, Peter D.
AU  - Mueller, Yvonne
AU  - Okba, Nisreen M.A.
AU  - Koopmans, Marion P.G.
AU  - Haagmans, Bart H.G.
AU  - Rokx, Casper
AU  - Rijnders, Bart J.A.
TI  - Convalescent Plasma for COVID-19. A randomized clinical trial
AID  - 10.1101/2020.07.01.20139857
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.01.20139857
4099  - http://medrxiv.org/content/early/2020/07/03/2020.07.01.20139857.short
4100  - http://medrxiv.org/content/early/2020/07/03/2020.07.01.20139857.full
AB  - Background After recovery from COVID-19, most patients have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an inexpensive and widely available treatment for COVID-19.Methods The Convalescent-plasma-for-COVID (ConCOVID) study was a randomized trial comparing convalescent plasma with standard of care therapy in patients hospitalized for COVID-19 in the Netherlands. Patients were randomized 1:1 and received 300ml of plasma with anti-SARS-CoV-2 neutralizing antibody titers of at least 1:80. The primary endpoint was day-60 mortality and key secondary endpoints were hospital stay and WHO 8-point disease severity scale improvement on day 15.Results The trial was halted prematurely after 86 patients were enrolled. Although symptomatic for only 10 days (IQR 6-15) at the time of inclusion, 53 of 66 patients tested had anti-SARS-CoV-2 antibodies at baseline. A SARS-CoV-2 plaque reduction neutralization test showed neutralizing antibodies in 44 of the 56 (79%) patients tested with median titers comparable to the 115 donors (1:160 vs 1:160, p=0.40). These observations caused concerns about the potential benefit of convalescent plasma in the study population and after discussion with the data safety monitoring board, the study was discontinued. No difference in mortality (p=0.95), hospital stay (p=0.68) or day-15 disease severity (p=0.58) was observed between plasma treated patients and patients on standard of care.Conclusion Most COVID-19 patients already have high neutralizing antibody titers at hospital admission. Screening for antibodies and prioritizing convalescent plasma to risk groups with recent symptom onset will be key to identify patients that may benefit from convalescent plasma. Clinicaltrials.gov: NCT04342182Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04342182Clinical Protocols https://www.sugarsync.com/pf/D6493122_09502780_0425619 Funding StatementErasmusfoundation YpsilonAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval by the IRB of the Erasmus MC University Medical Center in the Netherlands as well as the Dutch competent authority (CCMO) was received before the start of the studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data will be shared on reasonable request to non-for-profit organizations after review of the request and approval by the study team as long as the data sharing will serve a scientifically valuable purpose